Securities
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Track global pharma securities, IPOs, M&A, and investor insights. Essential intelligence for pharmaceutical investment and business development.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Securities hub for FDA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Atara Biotherapeutics Faces Securities Class Action Lawsuit with May 2026 Deadline for Lead Plaintiff Applications
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.